Global access disparity: difference between revisions
Diff·revision 10 → 11·20:35, 4 May 2025
Difference between revision 10 and revision 11 of Global access disparity. 6 lines changed; the page grew by 114 bytes.
| Revision 10 — 21:19, 21 Apr 2025 AppealsArno (talk) fix the anchor on an internal link 3,200 bytes +581 | Revision 11 — 20:35, 4 May 2025 CheckSumChase (talk) add the harm-reduction cross-link 3,314 bytes +114 | ||
|---|---|---|---|
| 31 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 31 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 32 | 32 | ||
| + | 33 | == See also == | |
| + | 34 | * [[Prior authorisation]] | |
| + | 35 | * [[Cost per milligram]] | |
| + | 36 | * [[Peptide harm reduction]] | |
| + | 37 | * [[Grey market]] | |
| + | 38 | ||
| 33 | {{DEFAULTSORT:Global access disparity}} | 39 | {{DEFAULTSORT:Global access disparity}} |
| 34 | [[Category:Health equity]] | 40 | [[Category:Health equity]] |